Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020)
Pulmonx's (LUNG) quarterly Preferred Stock Liabilities came in at $207.6 million in Q3 2020, up 1.1% year-on-year from $205.3 million in Q4 2019, and little changed on a QoQ basis from $207.6 million in Q2 2020.
Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Pulmonx (LUNG) has 2 years of Preferred Stock Liabilities data on file, last reported at $207.6 million in Q3 2020.
- On a quarterly basis, Preferred Stock Liabilities rose 1.1% year-over-year to $207.6 million in Q3 2020; TTM through Sep 2020 was $207.6 million, a 1.1% increase from a year earlier, with the FY2019 full-year figure at $205.3 million, up 46.11% from the prior year.
- Preferred Stock Liabilities for Q3 2020 stood at $207.6 million, roughly flat from $207.6 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for LUNG reached as high as $207.6 million in Q1 2020 and fell as low as $205.3 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Pulmonx | 49.94 Mn | -19.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 207.60 Mn |
| Jun 30, 2020 | 207.60 Mn |
| Mar 31, 2020 | 207.60 Mn |
| Dec 31, 2019 | 205.34 Mn |
| Sep 30, 2019 | 205.34 Mn |